First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients-Reference-Cited by-同舟云学术

First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients

Published:2020-05-26 Issue:2 Volume:105 Page:116-125
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Knauf Wolfgang¹,Dingeldein Gerrit²,Schlag Rudolf³,Welslau Manfred⁴,Moehler Thomas⁵^ORCID,Terzer Tobias⁶,Walter Sarah⁷,Habermehl Christina⁶,Kunz Christina⁶,Goldschmidt Hartmut⁸⁹,Raab Marc‐Steffen⁸,

Affiliation:

1. Centrum Haematologie & Onkologie Bethanien Frankfurt Germany

2. Onkologische Schwerpunktpraxis Darmstadt Germany

3. Hämatologisch‐Onkologische Schwerpunktpraxis Würzburg Germany

4. Onkologische Praxis Aschaffenburg Germany

5. IQVIA Frankfurt Germany

6. Department of Biostatistics German Cancer Research Center Heidelberg Germany

7. Koordinierungszentrum für klinische Studien Heidelberg, FRG Heidelberg Germany

8. Department of Medicine V University of Heidelberg Heidelberg Germany

9. National Center for Tumor Diseases (NCT) Heidelberg Germany

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13409

Reference32 articles.

1. Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry

2. Management of multiple myeloma in the newly diagnosed patient

3. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

4. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

5. Bortezomib in multiple myeloma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey;Journal of Chemotherapy;2023-05-21

2. Genome Instability in Multiple Myeloma: Facts and Factors;Cancers;2021-11-26

3. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV);Journal of Cancer Research and Clinical Oncology;2021-01-12

4. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma;Biological and Pharmaceutical Bulletin;2020-10-01

Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China

;Cancer Management and Research;2020-09